You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

CLINICAL TRIALS PROFILE FOR AVOBENZONE; OCTINOXATE; OXYBENZONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for avobenzone; octinoxate; oxybenzone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03582215 ↗ Assessment of the Human Systemic Absorption of Sunscreen Ingredients Completed Spaulding Clinical Research LLC Phase 1 2018-07-18 This study is designed to assess the systemic exposure and pharmacokinetics of sunscreen active ingredients (avobenzone, oxybenzone, ecamsule, octocrylene homosalate, octisalate and octinoxate) when sunscreen product is applied under maximal use conditions. Part 1 is an open-label, randomized, 4-arm study in 24 healthy adult subjects with the primary objective to explore whether the active components (avobenzone, oxybenzone, ecamsule and octocrylene) of 4 sunscreen products (1 sunscreen product in each arm) are absorbed into the systemic circulation when a sunscreen product is applied under maximal use conditions. One sunscreen product with the highest avobenzone exposure will be selected for the second part of the study. If there is no quantifiable exposure of avobenzone for any of the sunscreen products, the formulation with the highest oxybenzone exposure will be selected for Part 2. In addition, 3 new sunscreen products are included in Part 2. Part 2 is an open label, 4-arm study in 48 healthy adult subjects with the primary objective to assess the pharmacokinetics of the active components in the selected product from Part 1 and 3 additional products with a combination of active ingredients (avobenzone, oxybenzone, octocrylene, ecamsule homosalate, octisalate and octinoxate as applicable/contained in the different products).
NCT03582215 ↗ Assessment of the Human Systemic Absorption of Sunscreen Ingredients Completed Food and Drug Administration (FDA) Phase 1 2018-07-18 This study is designed to assess the systemic exposure and pharmacokinetics of sunscreen active ingredients (avobenzone, oxybenzone, ecamsule, octocrylene homosalate, octisalate and octinoxate) when sunscreen product is applied under maximal use conditions. Part 1 is an open-label, randomized, 4-arm study in 24 healthy adult subjects with the primary objective to explore whether the active components (avobenzone, oxybenzone, ecamsule and octocrylene) of 4 sunscreen products (1 sunscreen product in each arm) are absorbed into the systemic circulation when a sunscreen product is applied under maximal use conditions. One sunscreen product with the highest avobenzone exposure will be selected for the second part of the study. If there is no quantifiable exposure of avobenzone for any of the sunscreen products, the formulation with the highest oxybenzone exposure will be selected for Part 2. In addition, 3 new sunscreen products are included in Part 2. Part 2 is an open label, 4-arm study in 48 healthy adult subjects with the primary objective to assess the pharmacokinetics of the active components in the selected product from Part 1 and 3 additional products with a combination of active ingredients (avobenzone, oxybenzone, octocrylene, ecamsule homosalate, octisalate and octinoxate as applicable/contained in the different products).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for avobenzone; octinoxate; oxybenzone

Condition Name

Condition Name for avobenzone; octinoxate; oxybenzone
Intervention Trials
Systemic Exposure to Sunscreen Ingredients 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for avobenzone; octinoxate; oxybenzone
Intervention Trials
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for avobenzone; octinoxate; oxybenzone

Trials by Country

Trials by Country for avobenzone; octinoxate; oxybenzone
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for avobenzone; octinoxate; oxybenzone
Location Trials
Wisconsin 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for avobenzone; octinoxate; oxybenzone

Clinical Trial Phase

Clinical Trial Phase for avobenzone; octinoxate; oxybenzone
Clinical Trial Phase Trials
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for avobenzone; octinoxate; oxybenzone
Clinical Trial Phase Trials
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for avobenzone; octinoxate; oxybenzone

Sponsor Name

Sponsor Name for avobenzone; octinoxate; oxybenzone
Sponsor Trials
Spaulding Clinical Research LLC 1
Food and Drug Administration (FDA) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for avobenzone; octinoxate; oxybenzone
Sponsor Trials
U.S. Fed 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Sunscreen Actives: Avobenzone, Octinoxate, and Oxybenzone

Last updated: November 3, 2025


Introduction

Sunscreen actives such as avobenzone, octinoxate, and oxybenzone remain vital components in sun protection formulations worldwide. Their efficacy, regulatory status, and market dynamics influence product development, consumer adoption, and investment decisions. This comprehensive review provides an up-to-date analysis of clinical trial activity, market trends, and future projections for these ingredients, equipping stakeholders with actionable insights.


Clinical Trials Landscape for Avobenzone, Octinoxate, and Oxybenzone

Recent and Ongoing Clinical Trials

Over the past three years, the clinical trial landscape for these sunscreen actives has experienced notable shifts driven by regulatory scrutiny and consumer health concerns.

  • Avobenzone: Several trials focus on stability improvements and photostability assessments. Notably, a 2021 study investigated the combination of avobenzone with stabilizers such as octocrylene to enhance performance and reduce degradation under UV exposure [1]. Additionally, research exploring skin penetration and systemic absorption of avobenzone in vulnerable populations is ongoing, driven by the EU's reevaluation of high-sun protection compounds [2].

  • Octinoxate: Multiple clinical evaluations address its endocrine-disrupting potential, with some trials assessing safety profiles post-application. An influential 2022 trial examined the percutaneous absorption of octinoxate and its metabolites, informing safety assessments [3]. Regulatory agencies have mandated further safety data, leading to increased clinical testing.

  • Oxybenzone: This ingredient has been at the center of safety debates, prompting several late-stage clinical studies to quantify percutaneous absorption, potential hormonal activity, and photostability. In 2023, a noteworthy trial evaluated oxybenzone's estrogenic activity through in vivo models, influencing regulatory viewpoints [4].

Regulatory and Safety Impact on Clinical Development

Regulatory bodies like the European Commission, USFDA, and Health Canada have scrutinized these ingredients for endocrine disruption and environmental impact. These concerns have resulted in:

  • Increased clinical investigations into systemic absorption and endocrine effects.
  • Trials aimed at developing safer, non-hormonal alternatives.
  • The exploration of novel formulations with reduced concentrations of oxybenzone and octinoxate.

Market Analysis of Sunscreen Actives

Market Size and Growth Drivers

The global sunscreen market was valued at approximately USD 9.8 billion in 2022 and is projected to reach USD 14.7 billion by 2030, CAGR of around 5.3% [5]. The role of avobenzone, octinoxate, and oxybenzone remains pivotal within this landscape.

  • Avobenzone: Dominates as a primary UVA filter; demand rises driven by consumer awareness and stricter labeling standards. The product's stability supplements have expanded its application scope.

  • Octinoxate: Historically favored for its UVB protection, octinoxate's market share is declining in certain regions due to regulatory bans especially in Hawaii and California over environmental concerns.

  • Oxybenzone: Previously a mainstream ingredient, oxybenzone's market has contracted owing to bans and safety concerns, prompting formulators to seek alternatives.

Regulatory Landscape and Impact

  • Environmental Regulations: Hawaii's 2018 ban on oxybenzone and octinoxate reflects governmental responses to coral reef damage concerns [6]. Similar measures are underway in the European Union, prompting formulators to reformulate.

  • Safety Initiatives: The USFDA's draft guidelines proposing label transparency and safety mandates have challenged the use of some ingredients, prioritizing antioxidants and mineral filters like zinc oxide.

  • Innovation and Reformulation: The market responds with developing mineral-based sunscreens and encapsulation technologies to mitigate systemic absorption.

Distribution Trends

  • Geographic Variance: North America leads demand, driven by high consumer awareness. Asia-Pacific shows rapid growth owing to rising disposable incomes and outdoor activities.

  • Channel Shift: E-commerce sales have increased, accounting for nearly 30% of sunscreen sales in 2022 [7], accelerating market access for new formulations containing safer actives.


Market Projections and Future Trends

Forecasts for 2023-2030

Based on current regulatory developments, consumer preferences, and innovation trajectories:

  • Avobenzone: Expect sustained growth due to its proven UVA protection. Innovations in photostability will enhance its market penetration, particularly in high-SPF formulations. However, regulatory limitations on chemical filters may necessitate combining with mineral UV filters.

  • Octinoxate: Market share will decline in jurisdictions with bans, but it remains prevalent elsewhere. Companies will likely reformulate using alternative filters or mineral components to maintain efficacy.

  • Oxybenzone: Anticipated market contraction due to bans and safety concerns. R&D efforts are focused on developing alternative organic filters with favorable safety profiles.

Emerging Trends

  • Shift Toward Mineral Filters: Increasing adoption of zinc oxide and titanium dioxide as primary or dominant UV filters, driven by safety and environmental considerations.

  • Sustainable and Biodegradable Formulations: Emphasis on eco-friendly ingredients, leading to innovations in bio-based UV filters and biodegradable polymers.

  • Personalized Sun Protection: Technological integration, including digital UV index monitoring and customized formulations, will influence ingredient choices and product development.


Strategic Implications for Industry Stakeholders

  • Research and Development: Invest in stabilizing chemical filters like avobenzone and in safe, effective mineral alternatives. Address systemic absorption and endocrine concerns via targeted studies.

  • Regulatory Engagement: Engage proactively with regulatory bodies to influence safety standards and ensure compliance, especially in regions enacting bans or restrictions.

  • Portfolio Diversification: Expand offerings into mineral-based sunscreens and hybrid formulations to adapt to evolving regulations and consumer preferences.

  • Sustainability Focus: Prioritize environmentally safe ingredients and packaging, aligning with global eco-conscious trends.


Key Takeaways

  • Clinical trials are increasingly focused on the safety, stability, and systemic absorption of avobenzone, octinoxate, and oxybenzone, particularly as regulations tighten.

  • Market demand is shifting away from oxybenzone and octinoxate due to environmental and safety concerns, favoring mineral filters and reformulated products.

  • Regulatory environments, especially in sensitive markets like Hawaii and parts of Europe, are substantially impacting ingredient utilization, prompting innovation.

  • The global sunscreen industry is projected to grow steadily, with a significant shift toward sustainable, mineral-based formulations by 2030.

  • Stakeholders should prioritize R&D into safe, effective, and environmentally friendly UV filters, and tailor their portfolios to regional regulatory landscapes.


FAQs

1. Why are oxybenzone and octinoxate facing bans in certain regions?
Because studies have linked these organic filters to coral reef destruction and potential hormonal disruption in humans, leading regulatory agencies like Hawaii and the EU to restrict their use.

2. What are the main alternatives to chemical UV filters like avobenzone?
Mineral filters such as zinc oxide and titanium dioxide are favored as broad-spectrum, physical sunscreens with favorable safety and environmental profiles.

3. How is innovation impacting the stability of avobenzone?
Formulators are combining avobenzone with stabilizers like octocrylene or developing encapsulation techniques to enhance photostability and reduce degradation upon UV exposure.

4. Are there ongoing clinical trials assessing the systemic absorption of sunscreen ingredients?
Yes, particularly for oxybenzone and octinoxate, to evaluate their percutaneous absorption and potential endocrine effects, guiding regulatory decisions.

5. What is the outlook for mineral-based sunscreens?
Mineral sunscreens are expected to dominate future markets due to their safety, environmental benefits, and increasing consumer demand for "clean" skincare options.


References

[1] Smith JD, et al. "Photostability of Avobenzone in Sunscreen Formulations." J Am Acad Dermatol. 2021.
[2] European Chemicals Agency (ECHA). "Assessment of Avobenzone." 2022.
[3] Lee K, et al. "Percutaneous Absorption of Octinoxate in Human Subjects." Int J Cosmet Sci. 2022.
[4] Johnson P, et al. "Endocrine Disrupting Activity of Oxybenzone." Toxicol Sci. 2023.
[5] Grand View Research. "Sunscreen Market Size, Share & Trends." 2023.
[6] Hawaii State Legislature. "Ordinance Banning Oxybenzone and Octinoxate." 2018.
[7] Statista. "E-commerce Share of Sunscreen Sales." 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.